Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Lara Goscé

Biographic Data

ID7760725
NAMELara Goscé
GIVEN NAMESLara
FAMILY NAMEGoscé
SIGNATUREGOSCÉ L
AFFILIATIONSLondon School of Hygiene & Tropical Medicine
ORCID0000-0003-2392-6271
VERIFIEDYes
TOTAL WORKS8
TOTAL CITATIONS0
AUTHOR COUNT8
EDITOR COUNT0
FIRST PUBLICATION YEAR2019
LATEST PUBLICATION YEAR2025
H-INDEX0
  • Tuberculosis and the climate crisis in Latin America: A predicament of poverty, migration and displacement

    Open Access•Lara Goscé, Júlia Moreira Pescarini et al.•ARTICLE•BMJ Global Health•2025

    box Tuberculosis (TB) is a disease of poverty and social inequalities, and its burden has been increasing in Latin America in the past decade

  • Potential impact, costs, and benefits of population-wide screening interventions for tuberculosis in Viet Nam: A mathematical modelling study

    Open Access•Alvaro Schwalb, Katherine C Horton et al.•ARTICLE•PLOS Global Public Health•2025

    Population-wide screening may accelerate the decline of tuberculosis (TB) incidence, but the optimal screening algorithm and duration must weigh resource considerations. We calibrated a deterministic transmission model to TB epidemiology in Viet Nam. We simulated three population-wide screening algorithms from 2025: sputum nucleic acid amplification tests (NAAT, Xpert MTB/RIF Ultra) only; chest radiography (CXR) followed by NAAT; and CXR-only wit…

  • Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia

    Open Access•Lara Goscé, Amare Worku Tadesse et al.•ARTICLE•BMJ Global Health•2024

    BACKGROUND: Digital adherence technologies (DATs) with associated differentiated care are potential tools to improve tuberculosis (TB) treatment outcomes and reduce associated costs for both patients and healthcare providers. However, the balance between epidemiological and economic benefits remains unclear. Here, we used data from the ASCENT trial to estimate the potential long-term epidemiological and economic impact of DAT interventions in Eth…

  • Systematic review of the economic impact of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection compared with tuberculin skin test and interferon-gamma rel…

    Open Access•Lara Goscé, Kasim Allel et al.•ARTICLE•PLOS Global Public Health•2024

    The Purified Protein Derivative tuberculin skin tests (TST) and blood-based Mycobacterium tuberculosis (M . tb) specific interferon-gamma release assays (IGRA) are the currently used tests for identifying individuals with TB infection for preventive treatment. However, challenges around access and implementation have limited their use. Novel M . tb specific skin tests (TBST) such as Diaskintest, ESAT6-CFP10 (C-TST), C-Tb (also known as Cy-Tb), an…

  • Cost-effectiveness of diagnostic technologies for mycobacterium tuberculosis infection in India and Brazil

    Open Access•Saima Bashir, Shehzad Ali et al.•ARTICLE•PLOS Global Public Health•2024

    The economic value of new skin-based tests and blood-based interferon-γ release assays (IGRAs) for tuberculosis (TB) infection is not yet well-established. This study evaluates the cost and cost-effectiveness in two high-burden countries by comparing:(a) new skin-based tests(Diaskintest and Cy-Tb) with the purified protein derivative (PPD)-tuberculin test (TST);(b) IGRAs (Standard E TB-Feron ELISA (TBF))with approved IGRAs (QuantiFERON-TB Gold Pl…

  • Public health benefits of shifting from hospital-focused to ambulatory TB care in Eastern Europe: Optimising TB investments in Belarus, the Republic of Moldova, and Romania

    Open Access•Sherrie L Kelly, Gerard Joseph Abou Jaoude et al.•ARTICLE•PLOS Global Public Health•2023

    High rates of drug-resistant tuberculosis (DR-TB) continue to threaten public health, especially in Eastern Europe. Costs for treating DR-TB are substantially higher than treating drug-susceptible TB, and higher yet if DR-TB services are delivered in hospital. The WHO recommends that multidrug-resistant (MDR) TB be treated using mainly ambulatory care, shown to have non-inferior health outcomes, however, there has been a delay to transition away …

  • Economic evaluation of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: A modelling study

    Open Access•Lara Goscé, Kasim Allel et al.•ARTICLE•PLOS Global Public Health•2023

    Evidence on the economic impact of novel skin tests for tuberculosis infection (TBST) is scarce and limited by study quality. We used estimates on the cost-effectiveness of the use of TBST compared to current tuberculosis infection (TBI) tests to assess whether TBST are affordable and feasible to implement under different country contexts. A Markov model parametrised to Brazil, South Africa and the UK was developed to compare the cost-effectivene…

  • Protocol for a cluster randomised control trial evaluating the efficacy and safety of treatment for latent tuberculosis infection in recent migrants within primary care: The CatapuLT trial

    Open Access•Matthew Burman, Andrew Copas et al.•ARTICLE•BMC Public Health•2019

    NCT03069807, March 2017, registered retrospectively

No prominent works on this page.

  • Protocol for a cluster randomised control trial evaluating the efficacy and safety of treatment for latent tuberculosis infection in recent migrants within primary care: The CatapuLT trial

    Open Access•Matthew Burman, Andrew Copas et al.•ARTICLE•BMC Public Health•2019

    NCT03069807, March 2017, registered retrospectively

  • Public health benefits of shifting from hospital-focused to ambulatory TB care in Eastern Europe: Optimising TB investments in Belarus, the Republic of Moldova, and Romania

    Open Access•Sherrie L Kelly, Gerard Joseph Abou Jaoude et al.•ARTICLE•PLOS Global Public Health•2023

    High rates of drug-resistant tuberculosis (DR-TB) continue to threaten public health, especially in Eastern Europe. Costs for treating DR-TB are substantially higher than treating drug-susceptible TB, and higher yet if DR-TB services are delivered in hospital. The WHO recommends that multidrug-resistant (MDR) TB be treated using mainly ambulatory care, shown to have non-inferior health outcomes, however, there has been a delay to transition away …

  • Economic evaluation of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: A modelling study

    Open Access•Lara Goscé, Kasim Allel et al.•ARTICLE•PLOS Global Public Health•2023

    Evidence on the economic impact of novel skin tests for tuberculosis infection (TBST) is scarce and limited by study quality. We used estimates on the cost-effectiveness of the use of TBST compared to current tuberculosis infection (TBI) tests to assess whether TBST are affordable and feasible to implement under different country contexts. A Markov model parametrised to Brazil, South Africa and the UK was developed to compare the cost-effectivene…

  • Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia

    Open Access•Lara Goscé, Amare Worku Tadesse et al.•ARTICLE•BMJ Global Health•2024

    BACKGROUND: Digital adherence technologies (DATs) with associated differentiated care are potential tools to improve tuberculosis (TB) treatment outcomes and reduce associated costs for both patients and healthcare providers. However, the balance between epidemiological and economic benefits remains unclear. Here, we used data from the ASCENT trial to estimate the potential long-term epidemiological and economic impact of DAT interventions in Eth…

  • Systematic review of the economic impact of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection compared with tuberculin skin test and interferon-gamma rel…

    Open Access•Lara Goscé, Kasim Allel et al.•ARTICLE•PLOS Global Public Health•2024

    The Purified Protein Derivative tuberculin skin tests (TST) and blood-based Mycobacterium tuberculosis (M . tb) specific interferon-gamma release assays (IGRA) are the currently used tests for identifying individuals with TB infection for preventive treatment. However, challenges around access and implementation have limited their use. Novel M . tb specific skin tests (TBST) such as Diaskintest, ESAT6-CFP10 (C-TST), C-Tb (also known as Cy-Tb), an…

  • Cost-effectiveness of diagnostic technologies for mycobacterium tuberculosis infection in India and Brazil

    Open Access•Saima Bashir, Shehzad Ali et al.•ARTICLE•PLOS Global Public Health•2024

    The economic value of new skin-based tests and blood-based interferon-γ release assays (IGRAs) for tuberculosis (TB) infection is not yet well-established. This study evaluates the cost and cost-effectiveness in two high-burden countries by comparing:(a) new skin-based tests(Diaskintest and Cy-Tb) with the purified protein derivative (PPD)-tuberculin test (TST);(b) IGRAs (Standard E TB-Feron ELISA (TBF))with approved IGRAs (QuantiFERON-TB Gold Pl…

  • Tuberculosis and the climate crisis in Latin America: A predicament of poverty, migration and displacement

    Open Access•Lara Goscé, Júlia Moreira Pescarini et al.•ARTICLE•BMJ Global Health•2025

    box Tuberculosis (TB) is a disease of poverty and social inequalities, and its burden has been increasing in Latin America in the past decade

  • Potential impact, costs, and benefits of population-wide screening interventions for tuberculosis in Viet Nam: A mathematical modelling study

    Open Access•Alvaro Schwalb, Katherine C Horton et al.•ARTICLE•PLOS Global Public Health•2025

    Population-wide screening may accelerate the decline of tuberculosis (TB) incidence, but the optimal screening algorithm and duration must weigh resource considerations. We calibrated a deterministic transmission model to TB epidemiology in Viet Nam. We simulated three population-wide screening algorithms from 2025: sputum nucleic acid amplification tests (NAAT, Xpert MTB/RIF Ultra) only; chest radiography (CXR) followed by NAAT; and CXR-only wit…

Tuberculosis (8 works) · Medicine (7 works) · Tuberculosis Research and Epidemiology (7 works) · Pathology (5 works) · Mycobacterium tuberculosis (4 works) · Nursing (4 works) · Public health (4 works) · Economic growth (3 works) · Epidemiology (3 works) · Immunology (3 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae